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ABSTRACT 
 
Insulin like growth factor-1 receptor (IGF-1R) has been shown to be important for cancer cell growth 
and survival, and is often overexpressed in malignant and premalignant tissues. Ligand binding to 
IGF-1R induces transphosphorylation and activation of the receptor, leading to subsequent activation 
of the phosphatidyl inositol-3 kinase (PI3K), the mitogen-activated protein kinase (MAPK) and the 
14-3-3 pathways. Most of these pathways are shared by other receptor tyrosine kinases. Inhibition of 
these pathways using specific IGF-1R antibodies has, however, failed in large trials on cancer 
patients. This opens the possibilities for alternative signaling pathways.  Recently, IGF-1R was shown 
to be SUMOylated and translocated to the cell nucleus. In the nucleus it binds to enhancer-like regions, 
and regulates expression of genes including CCND1 and AXIN2, and phosphorylates Histone3. The 
expression of nuclear IGF-1R has also been linked to increased cell growth and aggressive phenotype 
in cancer. 
In paper I the effects of picropodophyllin (PPP), an inhibitor of IGF-1R, on cell cycle progression 
were studied. Previous studies have indicated that PPP treated cells arrest in G2/M. We found that 
PPP induced G2/M arrest through interfering with microtubule dynamics causing prolonged mitotic 
arrest and mitotic catastrophe in an IGF-1R independent manner. This mechanism of PPP may 
contribute to its efficacy in treatment of cancer patients. In paper II the roles of SUMOylated IGF-1R 
in regulating cell proliferation and cell cycle progression were investigated. We provided evidence 
that SUMOylation of IGF-1R increases G1/S phase transition through inducing expression of cyclins 
(D, A and B) and upregulating CDK2. Cells expressing SUMOylated IGF-1R also proliferated faster 
and formed more colonies in soft agar compared to cells expressing IGF1R with mutated SUMO-
binding sites. In paper III we investigated potential binding partners to nuclear IGF-1R in human 
embryonic stem cells (hESC).  We found that nuclear IGF-1R associates with PCNA and 
phosphorylates it, not only in hESCs but also in other cell types. The nuclear IGF-1R-induced PCNA 
phosphorylation was followed by ubiquitination of PCNA, probably through DNA damage tolerance 
(DDT)-dependent E2/E3 ligases (e.g. Rad18 and UBC13). Our data suggest that IGF-1R may 
contribute to activation of DDT, as externally induced DNA damage in IGF-1R negative cells led to G1 
cell cycle arrest and larger S-phase fork stalling compared to cells expressing IGF-1R. In summary, the 
achieved results may contribute in understanding the complexity of IGF-1R’s roles in cell growth and 
maintenance of genome stability, as well as the shown mitotic block induced by PPP may be a 
mechanism that favors anti-IGF-1R treatment in cancer.  
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1. List of abbreviations 
 
 
53BP1 : Tumor suppressor p53-binding protein 1 
ALS : Acid labile subunit 
APC : Anaphase promoting complex 
APIM : AlkB homolog 2 PCNA-interacting motif 
ATM : Ataxia telangiectasia mutated 
ATP : Adenosine tri-phosphate 
ATR : ATM- and Rad3-Related 
ATRIP : ATR-interacting protein 
Bad : Bcl associated death promoter 
Bak : Bcl-2 Homologous Antagonist-Killer Protein 
Bax : Bcl-2 associated X Protein 
Bcl : B-cell leukemia protein 
BRCA : Breast cancer susceptibility gene 
CAK : Cdk activating kinase 
Caspase : Cystine aspartic acid specific protease 
CDC : Cell division cycle protein 2 homolog 
CDK : Cyclin-dependent protein kinase 
cDNA : Complementary DNA (DNA copy of mRNA) 
CDT1 : CDC10-dependent transcript 1 
Chk : Checkpoint kinase 
Chk2 : Checkpoint kinase 2 
CKI : Cyclin dependent kinase inhibitor 
Co-IP : Co-immunoprecipitation 
DDR : DNA damage response 
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DDS : DNA damage silencing 
DNA : Deoxyribonucleic acid 
DNA-PK : DNA-dependent protein kinase, catalytic subunit 
DSB : Double strand break 
E2F : Transcription factor activating adenovirus E2 gene 
EGF : Epidermal growth factor 
EGFR : Epidermal growth factor receptor 
ERK1/2 : Extracellular signal-regulated kinase 1/2 
FGF : Fibroblast growth factor 
FGFR : Fibroblast growth factor receptor 
GDP : Guanosine diphosphate 
GH : Growth hormone 
Grb2 : Growth factor receptor-bound protein 2 
HCC : Hepatocellular carcinoma 
HLTF : Helicase-like transcription factor 
ICD : Intracellular domain 
ICF : Intermediate cell foci 
IGF-1 : Insulin-like growth factor 1 
IGF-1R : Insulin-like growth factor 1 receptor 
IGF-2 : Insulin-like growth factor 2 
IGF-2R : Insulin-like growth factor 2 receptor 
IGFBP : Insulin-like growth factor binding proteins 
INFS : Integrative nuclear FGFR1 signaling 
INK4 : Inhibitor of cdk4 
INTERNET : Integral trafficking from the ER to the nuclear envelope transport 
IR : Insulin receptor 
IR-A/B : Insulin receptor isoform A/B 
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IRS1-4 : Insulin receptor substrate 1-4 
kDa : Kilo Dalton 
KIP : Cdk inhibitory protein 
M6P : Mannos-6-phosphate 
mAb : Monoclonal antibodies 
MAPK : Mitogen activated protein kinase 
MCL-1 : Myeloid leukemia cell differentiation protein 
MCM : Minichromosome maintenance 
MDC1 : Mediator of DNA damage checkpoint protein 1 
MDM2 : Murine double minute 2 
MEK : Mitogen-activated/Extracellular Regulated kinase 
MMS : Methyl methanesulfonate 
mRNA : Messenger ribonucleic acid 
mTOR : Mammalian target of rapamycin 
Nedd4 : Neural precursor cells-expressed developmentally down-regulated 4 
NHEJ : Non-homologous end joining repair 
NLS : Nuclear localization sequence 
NSCLC : Non-small cell lung cancer 
ORC : Origin recognition protein complex 
PCNA : Proliferation cell nuclear antigen 
PDGF : Platelet-derived growth factor 
PDGFR : Platelet-derived growth factor receptor 
PDK : Phosphoinositide-dependent protein kinase 
PI3K : Phosphatidylinositol-3’-kinase 
PI3P : Phosphatidylinositol 3,4,5-triphosphate 
PKB : Protein kinase B 
PLA : Proximity ligation assay 
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PLK1 : Polo-like kinase 1 
Post-RC : Post-replication complex 
PPP : Picropodophyllin 
Pre-IC : Pre-initiation complex 
PTB : Phospho-tyrosine binding domain 
Raf : V-raf-1 murine leukemia viral oncogene homolog 1 
Ras : Human homologue of Rat sarcoma 
RB : Retinoblastoma 
RFC : Replication factor C 
RING : Really interesting new gene 
RNA : Ribonucleic acid 
RNF : Ring finger protein 
RPA : Replication protein A 
rRNA : Ribosomal RNA 
RSK1 : Ribosome S6 kinase 1 
 
RT : Room temperature 
RTK : Receptor tyrosine kinase 
SCF : Skp, Cullin, Fbox 
SH : Src homology 
Shc : Src homology and collagen 
SHPRH : SNF2 histone linker PHD RING helicase 
Sos : Son of sevenless 
Src : V-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog 
SSB : Single strand break 
ssDNA : Single strand DNA 
SUMO : Small ubiquitin-related modifier 
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TK : Tyrosine kinase 
TLS : Translesion synthesis 
TOPBP1 : Topoisomerase binding protein 1 
TOPO : Topoisomerase 
Ub : Ubiquitin 
UBC : E2 ubiqution-conjugating protein 
UV : Ultra-violet 
VEGFR : Vascular endothelial growth factor receptor 
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Introduction 
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2. Chapter 1 
Cancer 
 
2.1 How cancer arises 
Normally human adult cells are specialized, i.e. each cell type has a specific function to preform within 
the tissue. As cells grow old or become damaged, they will die and new cells will divide and grow to 
replace them. This process is usually controlled by signals that regulate the division process and later 
on the specialization of the newly formed cells. As cancer develops, this control process breaks down 
and damaged cells continue to grow and divide in un-controlled manner, giving rise to a benign or a 
malignant tumor. 
A tumor is defined malignant if the cancerous cells start to invade neighboring tissues or use the blood 
or the lymph system to travel and spread throughout the body. A benign tumor does not spread or 
invade other tissues, and when removed usually does not recur.  
 
2.2 Hallmarks of cancer 
The traits normal cells acquire during transformation process to cancerous cells  are known as the 
hallmarks of cancer as defined by Hananhan & Weinberg (1,2), which include six main hallmarks, 
discussed below, and four emerging hallmarks including genome instability, deregulated metabolism, 
evading immune system and inflammation. 
 
2.2.1 Sustained proliferation signaling  
Normally the division of cells is controlled by signals that maintain the hemostasis of the cell number 
and function within a tissue. These signals are mediated in large, by growth factors and hormones that 
bind to cell surface receptors and transmit the signals intracellularly through cascades of protein 
interactions known as signaling pathways for the proper respond. 
Cancer cells on the other hand, are the masters of their own destiny. They evade these controlling 
signals through a variety of mechanisms which include: 1) Producing the growth factor ligands 
themselves; 2) Stimulating the normal cells within the tumor stroma, known as tumor-associated 
fibroblasts, to produce growth factors; 3) Increasing number of growth factor receptors, or acquiring 
structural alteration in the receptor molecules that facilitate ligand-independent activation; and 4) 
Constant activation through somatic mutations of components of signaling pathway components 
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downstream of these receptors. These components are known as cancer drivers and are either proto-
oncogenes, DNA repair genes or tumor suppressor genes. 
Proto-oncogenes are genes regulating normal cell proliferation. When altered in certain ways or 
become more active than normal, they may become cancer-causing genes (or oncogenes).  DNA repair 
genes are involved in repairing damaged or mutated DNA. Tumor suppressor genes are discussed 
below. 
 
2.2.2 Evading growth suppressors 
In addition to mutations in proto-oncogenes which induce and increase cellular proliferation, cancer 
cells must acquire mutations in another group of cancer drivers known as tumor suppressor genes. 
Tumor suppressor genes are involved in negatively regulating cell proliferation in a manner opposite to 
oncogenes, serving to protect cells from uncontrolled division. Cells with certain alterations in tumor 
suppressor genes, resulting from loss or reduction of functions, may divide in an uncontrolled manner. 
 
2.2.3 Resisting cell death 
Apoptosis is a process of controlled and regulated cell death when cells become old, malfunctional, no 
longer needed or pose a threat to the organism. The apoptotic machinery is composed of upstream 
regulators and downstream effectors. The regulators are either receiving extracellular death-inducing 
signals (extrinsic apoptotic program; Fas ligand/Fas receptor), or sensing a variety of intracellular 
signals (intrinsic apoptotic program) including DNA damage, insufficient survival factors or 
hyperactivation of certain oncoproteins. Both regulators induce apoptosis through activation of 
downstream latent protease effectors known as caspases that leads to dissembling and consumption of 
the cell by both its neighbor cells and phagocytic cells. Cancer cells have evolved a variety of 
mechanism to evade apoptosis including: 1) Loss of DNA damage sensors; 2) Increased expression of 
antiapoptic regulators; 3) Downregulation pro-apoptotic factors. 
 
2.2.4 Enabling replicative immortality  
Normal cells are able to proliferate through a limited number of cell divisions before entering a non-
proliferative state known as senescence, or entering into a state called crisis which involves cell death. 
This limited number of cell division is linked to telomeres, multiple hexanucleuotide tandem repeats 
that protect the end of chromosomes from chromosomal DNA end-to-end fusion. The length of 
telomeric DNA is shortened through every round of cell division, driving the cells into a state of 
senescence or crisis after a certain number of cell divisions. Cancer cells, and other immortalized cells 
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nay process an enzyme called telomerase, a specialized DNA polymerase that add more segments to 
the end of telomeres, resulting in evading senescence and acquiring unlimited proliferation capacity.  
 
2.2.5 Inducing angiogenesis  
Like normal cells, cancer cells need the continuous supply of oxygen and nutrients and the ability to get 
rid of metabolic wastes. This is performed by the ability of cancer cells to induce angiogenesis or the 
formation of new blood vessels. The formation of new blood vessels is essential during embryological 
development, and postnatal in certain physiological processes, like wound healing and female 
reproductive cycle. However, in cancer cells the angiogenic switch is always turned on. 
 
2.2.6 Activating invasion and metastasis 
Metastasis is the ability of cancer cells to invade and spread throughout the body. It starts with local 
invasion, then intravasation through a nearby blood or lymphatic vessel, and use them to travel and 
spread to distant tissues. Then the escape of cancer cells from lumen of the vessels to the parenchyma 
of the distant tissues starts, leading to formation of nodules of cancer cells. 
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3. Chapter 2 
Growth factors and cell signaling 
 
3.1 Ligands 
In multi-cellular organisms, cells communicate with each other though physical interactions or via a 
group of communication molecules known as ligands. These two types of interactions allow cells to 
receive signals from outside and deliver them intracellularly for the proper respond and co-ordination 
with other cells.  
These ligands are divided into two groups; hydrophobic molecules that can pass directly through the 
phopholipid layer of the plasma membrane, and interact with intracellular proteins, and hydrophilic 
molecules which cannot pass through the phopholipid layer and must interacts instead with plasma 
membrane-associated proteins.  
 
3.2 Receptor tyrosine kinase family 
One of the largest classes of membrane receptors are a group of trans-membrane proteins known as 
enzyme-linked receptors. Ligand binding to the extracellular side of the receptor activates the receptor 
enzymatic activity on the intracellular side, and allows the transmission of the signal through a cascade 
of interactions between intracellular proteins. The majority of receptors in this class belong to receptor 
tyrosine kinase (RTKs) family, a group of membrane associated receptors with protein tyrosine kinase 
enzymatic activity, which catalyze the transfer of a phosphate group from ATP to certain tyrosine 
residues on the target protein.  
The general structure of RTKs is very similar, with an intracellular domain that possess the tyrosine 
kinase activity, an extracellular domain to which ligands bind to and a hydrophobic transmembrane 
domain connecting them together. In the non-activated form, majority of RTKs exist as monomers in 
the cell membrane, with the exception of insulin-like growth factor 1 receptor (IGF-1R)/insulin 
receptor (IR) family that exist as disulfide linked dimers of two different polypeptide chains (α and β) 
forming a heterodimer. Ligand binding induces receptor dimerization and autophosphorylation by 
bringing two monomers together, allowing the kinase domain of one RTK monomer to phosphorylate 
the other and vice versa .(3)  
RTKs are further subdivided into 20 different families based on the similarity in the primary structure 
and the functional domain composition in the extracellular and intracellular domains of the receptor.  
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3.2.1 The IGF Family 
The IGF system consists of three ligands (insulin, IGF-1 and IGF-2), at least four cell membrane 
receptors (IR, with two isoforms [IRA, IRB], IGF-1R and IGF-2R) and six high-affinity binding 
proteins (IGFBP 1-6) in addition to the IGF-1R/IR hybrid receptor (4,5). 
 
3.2.1.1 Insulin 
The human insulin gene, INS, is located on the short arm of chromosome 11. Insulin is produced in the 
pancreas by beta cells of the islets of Langerhans as proinsulin (6). However, the biologically active 
form of insulin is a monomer consisting of two chains, an A chain composed of 21 amino acids and a B 
chain composed of 30 amino acids, linked by two disulfide bridges.  
The binding of the hormone to its receptor results in the increased uptake of glucose into the cells, 
where it is converted into metabolic energy or stored as glycogen or fat (7). Most studies suggest that 
the metabolic functions of insulin are mainly mediated through insulin receptor isoform B (IR-B), and 
the mitogenic functions are mediated through the insulin receptor isoform A (IR-A) (8-10). They both 
exhibit the same affinity for insulin ligand; however, IRA exhibits a higher affinity for IGFs, especially 
for IGF-2 (9). 
 
3.2.1.2 Insulin-like growth factor 1 (IGF-1)  
The human IGF-1 gene, IGF1, is located on the long arm of chromosome 12 (11). IGF1 has two 
promoter sites, and initiation of transcription from different promoters, in addition to alternative 
splicing creates multiple transcripts of IGF1(12). IGF-1 is a 70 amino acid polypeptide with a 
molecular mass of about 7.5 kDa, sharing 49% homology with insulin and 62% homology with IGF-2 
(13,14). IGF-1 production is regulated mainly by growth hormone (GH), in addition to other hormones 
and growth factors including follicle-stimulating hormone (FSH) and epidermal growth factor (EGF) 
(15,16). Levels of IGF-1 in the blood varies between 100-200 ng/ml in adults, but also varies 
substantially with age, increasing slowly from birth to puberty, surging during puberty and declining 
thereafter (17). IGF-1 mediates its effect through binding to IGF-1R, where it can regulate proliferation, 
differentiation, apoptosis and anabolic functions by increasing amino acids uptake (15,16). 
 
3.2.1.3 Insulin-like growth factor 2 (IGF-2) 
The human IGF-2 gene is located on the distal end of the short arm of chromosome 11, 1.4 kb 
downstream of the insulin gene  (18). IGF-2, like IGF-1, is a single polypeptide, with a molecular mass 
of about 74 kDa (19). IGF-2 displays parental imprinting. Thus, IGF-2 is expressed only from the 
paternal allele, while the maternal allele being transcriptionally silent (20). IGF-2 has four promoter 
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sites, with the first promoter expressed mainly in adults and promoters 3 and 4 in fetal development 
(12). Levels of IGF-2 in the blood varies between 400-600 ng/ml in adults, and mostly stable after 
puberty (21). However, GH has no regulatory role on IGF-2 (12). 
Like IGF-1, IGF-2 mediate its action through binding to IGF-1R, however IGF-1 binds to IGF-1R with 
2-15 folds higher affinity than IGF-2 (12).  IGF-2 plays an important role in embryonic and fetal 
development, as mitogenic and anti-apoptotic ligand. Whereas its role in the postnatal appears to be less 
important (22).  
 
3.2.1.4 IGF binding proteins and IGFBP proteases 
IGFs are usually found associated with one of the six known high-affinity binding proteins (IGFBP-1 to 
6) in the bloodstream and other biological fluids and tissues. IGFBPs function in regulating the 
interaction between IGFs and IGF-1R, in protecting IGFs from degradation and in transportation of 
IGFs throughout the blood (23-25). IGFBPs expression are regulated by a number of hormones 
including GH, FSH, estrogen, insulin, vitamin D, in addition to growth factors like FGF, EGF, PDGF 
and IGFs as well (12). 
IGFBP-3 is the predominant IGFBP in serum. Most circulating IGF-1 and IGF-2 form a ternary 
complex with IGFBP-3 and a third component, the acid-labile subunit (ALS), in a 1:1:1 molar ratio 
(26-28). In addition to regulating IGF bioavailability, IGFBPs have also IGF independent functions. 
IGFPB-3 and IGFBP-5, in particular, have been shown to regulate proliferation and  apoptosis 
independent of their effects on IGF-1R signaling (27). 
IGFBP proteases are a group of proteases which can cleave intact IGFBPs into small fragments, 
thereby altering their IGF-binding capacities. This family of molecules is heterogeneous, including 
serine proteases, cathepsins, and matrix metalloproteinases (16,26). For example, prostate-specific 
antigen (PSA), a serine protease, is able to cleave IGFBP-3 and 5, reducing their affinities towards IGF-
1 and restoring the mitogenic activity of IGF-1(12). The regulation of IGFBP proteolysis remains 
poorly understood, some of these proteases act preferentially within specific tissues, whereas others 
function in the bloodstream and extracellular space (12). 
 
3.2.1.5 IR/IGF receptors 
IGF-1R and IR belong to receptor tyrosine kinases (RTK) super family. IGF-1R/IR mediates the 
biological effects of the IGF ligands; IGF-1 functions primarily by activating the IGF-1R, insulin by 
activating IR, whereas IGF-2 can act through either the IGF-1R or through the IR-A isoform (9). IGF-R 
and IR share a high homology of (70%) especially within the tyrosine kinase domain (84%) (29,30), 
whereas IGF-1R and IGF-2R differ completely in structure. The structure of IGF-1R is show in (Fig.1) 
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The IGF-1R is synthesized as a single pre-protein with a 30-amino acid signal peptide that is cleaved 
after translation. The protein is then glycosylated, dimerized and transported to the Golgi apparatus, 
where it is processed as α- and β-subunits. These subunits, form a tetramer (β-α-α-β) through disulfide 
bonds, and then transported to the plasma membrane (31-33). The mature cell membrane-bound IGF-
1R consists of two 130- to 135-kDa extracellular α-chains, to which ligands bind to, and two 90- to 95-
kDa β-chains, which contain the tyrosine kinase domain, with several α–α and α–β disulfide bridges 
(34).  
The α-subunit is entirely extracellular and forms a dimer with the other α-subunit. The α-subunit 
contains two homologous domains, L1 and L2, separated by a cysteine-rich domain. (Fig.1). The 
cysteine-rich domain is also conserved in the IR  and the ligand binding pockets of IGF-1R and IR are 
formed by the extracellular α-subunits and possibly some extracellular portions of the β-subunits 
(30,35,36). Differences in receptor-ligand specificities are likely to be dictated by sequence differences 
within these regions. Indeed, lower homology between IGF-1R and IR is found in the amino-acid 
sequences of the C-terminal of the α-subunits (47%), extracellular cysteine-rich domains (48%), and N-
terminal portion of the β-subunits (41%).  
The β-subunit spans the plasma membrane and has three domains; the extracellular, transmembrane 
and intracellular domains (Fig.1). The intracellular part of β-subunit can be divided into a 
juxtamembrane, a tyrosine kinase (TK) and a C-terminal domain (Fig.1). The homology between IGF-
1R and IR at these domains are different. The TK domain exhibits the highest homology between the 
two receptors (84%) and the juxtamembrane domain shares 61% of homology, whereas the C-terminal 
domain shares only 44% (30). Despite this high degree of homology, experimental evidences suggest that 
the two receptors have distinct biological roles. 
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Figure 1. Schematic representation of IGF-1R/IR structure. IGF-1R/IR are composed of two α-
chains and two β-chains connected by disulphide bridges. The α-subunit is composed of L1, L2 and 
cysteine rich domains (CR), while the β-subunit is composed of juxtamembrane domain (JM), tyrosine 
kinase domain (TK) and C-terminal domain (C-Tail) (37). 
The IGF-2R, also called the cation-independent mannose-6-phosphate receptor (CI-MPR), is a multiple 
ligand-binding cell surface receptor. IGF-2R ligands are divided into those containing mannose-6-
phosphate (M-6-P) and those that are mannose-6-phosphate free. Some M-6-P-bearing ligands include 
leukemia inhibitory factor, proliferin and cathepsin D(38). Among IGF-2R ligands without M-6-P, 
including insulin-like growth factor 2, and retinoic acid (38). IGF-2R functions to clear IGF-2 from the 
cell surface to attenuate signaling. After binding IGF-2 at the cell surface, IGF-2R accumulates in 
forming clathrin-coated vesicles and is internalized (39,40). 
 
3.2.2 IGF signaling 
The multiple cellular responses that IGF-1 elicits could be explained by the fact that IGF-1R is able to 
activate at least three distinct downstream signaling pathways (Fig. 2). The first step in the IGF-1 
signaling pathway is the activation of the receptor. Mutations of the three tyrosines of the TK domain 
(Y1131, Y1135/1136) result in an almost but not completely, inactive receptor (41), while mutations at 
the K1003, in the ATP binding site, result in a dead receptor (42-44).  
As a consequence of ligand-induced autophosphorylation, the receptor will acquire and display a 
characteristic array of phosphotyrosine residues on its cytoplasmic tail. These phosphotyrosines 
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become recruiting sites for various cytoplasmic proteins, which will then transmit the signal through 
signaling pathways to mediate the effects of the ligand. 
 
3.2.2.1 The phosphoinositide 3-kinases, PI3-kinase (PI3K)/AKT pathway 
One of the first molecules that reach full activation after phosphorylation of tyrosine residues of 
intracellular subunit of IGF-1R is the insulin receptor substrate -1 (IRS-1). IRS-1 has three domains: an 
N-terminal pleckstrin homology (PH) domain, a phosphotyrosine-binding domain (PTB) and a C-
terminal domain with more than 20 potential phosphorylation sites interacting with SH2 domain-
containing proteins, including Grb2 and regulatory subunit of PI3K (p85) (45). 
IRS-1 interaction with p85, leads to activation of catalytic subunit p110 of PI3K and inducing the 
production of phosphoinsitol 3,4,5 triphosphate (PI3P) (46). In addition, p85 can also bind directly to 
the phosphorylated intra-cytoplasmic region of IGF-1R. These PI3P will serve as docking sites for 
pleckstrin-homology (PH) domain-containing proteins including AKT (Protein Kinase B, PKB), and its 
upstream activator 3-phosphoinositide-dependent protein-kinase 1 (PDK1). Akt/PKB is a 
serine/threonine kinase, which interacts with PI3P causing its translocation to the inner membrane and 
then phosphorylated by PDK1 on T308. For full activation AKT needs to be activated on S473 by 
target of rapamycin complex 2 (TORC2) (47), and DNA-activated protein kinase (DNA-PK) (48). 
The activated AKT/PKB will then activate several targets, including phosphorylation of and 
sequestration of the pro-apoptotic factor Forkhead-1 in the cytoplasm (49,50), inhibition of other pro-
apoptotic factors including BAD (51), activation of MDM2 leading to its translocation inside the 
nucleus, where it binds P53 and targets it for ubiquitination and degradation (52). Akt activation can 
also induce activation of TORC1, that will lead to phosphorylation of the 40S ribosomal S6 protein by 
the p70S6 kinase (53), affecting protein-synthesis machinery and cell cycle machinery (54-56). 
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Figure 2. Signaling pathway stream of the IGF-1R. IGF-1R/IR autophosphorylation induced by 
ligand binding leads to activation of two main pathways the MAPK pathway and the PI3K/AKT 
pathway. These two pathways then mediate the cellular functions of the IGF-1R, for example induction 
of cell growth and proliferation, cell survival and motility (57). 
  
3.2.2.2 The Mitogen activated protein kinase (MAPK) pathway 
Following activation of the IGF-1R kinase, SH2-containing protein Src homology and collagen (Shc) 
becomes activated by phosphorylation and forms a complex with the second adaptor protein, the 
growth factor receptor-binding protein 2 (Grb2). Grb2 can be activated also by binding directly to IRS-
1 via its SH2 domain. Grb2 binds to a guanine nucleotide exchange protein called the son of sevenless 
(SOS), binding of Grb2 to SOS leads to the activation of SOS activity and stimulate the exchange of 
GDP into GTP from a member of the Ras subfamily (58). Ras protein is able to interact physically with 
several alternative downstream signaling partners. The first of Ras effectors is the Raf serine/threonine 
kinase. The activation of Raf by Ras depends upon the relocalization of Raf within the cytoplasm (Ras 
proteins are always anchored to the inner surface of the plasma membrane through their C-terminal 
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hydrophobic tails) (59). Once activated, Raf proceeds to phosphorylate and activate a second kinase 
known as MAP kinase kinase (MEK). MEK, a serine/threonine and tyrosine kinase will phosphorylate 
two other kinases, the extracellular signal-regulated kinases 1 and 2, commonly referred to as ERK1 
and ERK2 (60,61). ERK kinases then phosphorylate several cytoplasmic substrates including Mnk1 
kinase as well as translocate to the nucleus, where they can phosphorylate several transcription factors 
including Ets and Jun (62,63).  
 
3.2.2.3 The 14-3-3 pathway 
The 14-3-3 is a family of regulatory proteins that bind to serine/threonine-phosphorylated residues.  By 
interacting with various regulatory proteins, 14-3-3 participates in diverse signal transduction pathways, 
although the role of 14-3-3 in many cases remains elusive. 14-3-3 can interact with phosphorylated 
IRS-1 or with the phosphoserine residues within the C-terminus of the IGF-1R. Some insights have 
been gained from investigations involving 14-3-3 functions on Raf-1 and BAD (64-66).  
14-3-3 maintains Raf-1 in an inactive state in the absence of activation signals, by binding to the N-
terminal domains, and promotes Raf-1 activation , by binding to the C-terminal domain,  when such 
signals are received (64,65). 14-3-3 is also involved in preventing apoptosis through inhibiting the 
interaction of BAD with Bcl-XL and Bcl-2. When Bad is phosphorylated, by survival signals-stimulated 
kinases, such as PKB, Raf-1, it becomes complexed with 14-3-3 in the cytosol, sequestered from 
mitochondrially localized Bcl-XL/Bcl-2 and unable to induce apoptosis (66).  
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4. Chapter 3 
Nuclear translocation of RTKs 
 
4.1 Endocytosis and Ubiquitination of RTKs 
Following ligand binding, virtually all RTKs are rapidly endocytosed. Most of the RTKs are 
endocytosed through clathrin-coated pits pathway, which then shed the clathrin and fuse with an 
endosome to form an early endosome. From the early endosome, the internalized receptor can then be 
recycled back to the membrane if the ligand can be dissociated from the receptor in the low pH of the 
early endosome, or sorted into late endosome and vesicles within the multi-vascular bodies (MVBs) for 
lysosomal degradation (67)  
In addition to clathrin mediated endocytosis, RTKs can be internalized through several clathrin-
independent endocytic mechanisms, including macropinocytosis, phagocytosis, and lipid raft-mediated 
(e.g., caveolin-mediated) endocytosis, and among them, macropinocytosis and lipid raft-mediated 
endocytosis have been reported for RTK internalization (68) 
The leading model for RTK clathrin mediated endocytosis suggests ubiquitination as the mechanism to 
recruit RTKs to clathrin-coated pit through interaction with proteins containing ubiquitin-binding 
domains (UBDs) in the clathrin-coated pit (67). Ligand binding to RTKs induces autophosphorylation 
of tyrosine residues in the cytoplasmic domain, which serves as binding site for RTK ubiquitination 
enzymes, a posttranslational modification by the covalent binding of the ubiquitin polypeptide to lysine 
residues of the target protein. The model assumes that ubiquitin modification recruits RTKs to the 
clathrin-coated pit through interaction with three UBD-containing proteins residing in clathrin-coated 
pits (epsin-1/2, Eps15, and Eps15R) (67). However, there are contradicting data regarding the 
importance of these proteins in EGFR and other RTKs’ internalization (69,70). 
One large family of E3 ligases that ubiquitinate RTKs is the RING finger containing ubiquitin ligases, 
such as Cbl. Cbl was shown to bind to and ubiquitinate EGFR, PDGFR, VEGFR, FGFR, IGF-1R, 
hepatocyte growth factor (c-Met), as well as other RTKs (71-74). c-Cbl knockout, siRNA depletion, or 
overexpression of inactive Cbl mutants inhibit internalization of EGFR and several other RTKs 
(67,75,76).  
Two other E3 ligases, Nedd4 and Mdm2, have been shown to mediate IGF-1R ubiquitination (77-80). 
Although exactly how c-Cbl interacts with IGF-1R remains largely unknown, Mdm2 and Nedd4 have 
been shown to bind to adaptor molecules β-arrestin and Grb 10, respectively (77,79,80). However, 
other studies showed that ubiquitin-conjugation sites of EGFR, FGFR-1 were not essential for 
ubiquitination, but only essential for IGF-1R internalization and endocytosis (76,81,82). 
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4.2 Nuclear and sub-cellular trafficking of RTKs 
In addition to recycling of the receptor and lysosomal degradation, internalized receptor can undergo 
retrograde trafficking, the transport of protein and lipid from the cell surface to Golgi and from the 
Golgi to Endoplasmic reticulum (ER) in coat protein complex I (COPI) coated vesicles, or even to the 
nucleus (68,83,84). 
The first example of retrograde trafficking was shown for EGFR. In response to EGF stimulation, a 
portion of EGFR would redistribute to the Golgi and the ER, with its C-terminus exposed to the 
cytoplasm and the N-terminus resides within the lumen of Golgi/ER. Blockage of the Golgi-to-ER 
retrograde trafficking through dissembling COPI complex inhibited EGFR transport to both the ER and 
the nucleus (84). In addition, inhibition of receptor endocytosis blocked the nuclear transport of EGFR, 
ErbB-2 and FGFR. Furthermore, ErbB-2 and EGFR have been shown to be associated with endosomal 
marker in the nucleus, suggesting the nuclear transport to be mediated by early endosomal sorting 
(85).After reaching the ER, RTKs can be transported to the nucleus via two importin-β-dependent 
pathways, integrative nuclear FGFR-1 signaling (INFS) and integral trafficking from the ER to the 
nuclear envelope transport (INTERNET). For the INFS pathway, characteristic of FGFR (86), the RTK 
is pumped through the Sec61 complex, a protein complex that transports proteins across ER, into the 
cytosol where it binds to cytosolic importin and transported into nucleus through the importin-nuclear 
pore complex interaction. For the INTERNET pathway, characteristic of EGFR and ERbB-2 (87), the 
receptor is transported along ER, translocated from the outer nuclear membrane to the inner nuclear 
membrane  by binding to ER-associated importin, all members of EGFR family contain nuclear 
localization signal (NLS) required for complex formation with importin-β. The RTK is then released 
into the nucleoplasm by the Sec61 complex (68). 
To date, 18 different RTKs have been reported to translocate to cell nucleus in respond to ligand 
stimulation. In addition to the nuclear transport of the intact receptor, several RTKs translocate in the 
form of receptor fragment called intracellular domain (ICD), generated by proteolysis, internal 
translation initiation or messenger RNA (mRNA) splicing (88).  
 
4.3 Nuclear trafficking of IGF-1R 
The nuclear localization of IGF-1R has been shown in a number of previous studies (89-93) and 
nuclear IGF-1R has been associated with many types of cancers including lung, breast, and prostate 
cancers, and hepatocyte carcinoma (89,93). However, until recently the exact mechanism of nuclear 
translocation of IGF-1R remained largely unknown. Earlier studies showed that IGF-1R and IR could 
be cleaved by γ-secretase complex to produce intra-cellular domain (ICD) fragments (94,95), with the 
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IR-ICD fragment localized to the cell nucleus (95). However, more recent studies have showed the 
translocation of the intact IGF-1R to the cell nucleus after SUMOylation on three lysine residues 
(Lys1025, Lys1100 and Lys1120) (90). Nuclear translocation of IGF-1R was shown to be mediated 
through nuclear pore complex after interacting with β-importin and SUMOylation of the receptor was 
shown to be required for the interaction with RanBP2 nuclear pore complex protein (91). However, 
further investigation is needed to identify mechanism of transportation of IGF-1R from endocytic 
vesicle to nuclear pore complex. 
 
4.4 Nuclear functions of RTKs 
Nuclear RTKs, either as intact receptors or as truncated fragments of the receptors, have been shown to 
mediate several nuclear functions, including modification and remodeling of histones (96-98), 
regulating DNA repair and DNA replication (99-101), transcription co-activation of several genes 
including cyclin D (92,102,103) and cyclooxygenase-2 (Cox-2) (104,105) through binding to 
transcriptions factors as STAT3&5 (106,107), LEF (92).   
Nuclear functions of IGF-1R are associated mainly with the translocation of the intact receptor, with 
the exception of the single study showing the accumulation of α-subunit of IGF-1R after IGF-1 
treatment in Graves’ disease fibroblasts. Nuclear IGF-1R was shown to associate with LEF-1 
transcription factor to regulate cyclin D1 expression (92), and regulate histone remodeling through 
phosphorylating histone 3 at tyrosine 41(96). Furthermore, in the current study we showed nuclear IGF-
1R to associate with and phosphorylate PCNA, regulating PCNA ubiquitination and DNA damage 
response and to regulate cell cycle progression through increasing expression of cyclins D, A,B and 
CDK2 (108). 
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5. Chapter 4 
Targeting RTKs as therapeutic approach 
 
5.1 Targeted therapy 
Surgery, chemotherapy and radiotherapy alone or in combination have been the conventional methods 
for cancer treatment. However due to the toxic effect of conventional treatments on normal cells, more 
interest is drawn towards a new treatment method called targeted therapy (109). Targeted therapy aim 
to block specific proteins or pathways related to carcinogenesis and tumor growth that is highly 
upregulated in that type of tumor, instead of targeting both normal and tumor cells (110). Various 
targeted therapies have been approved for cancer treatment including, apoptosis inducers, angiogenesis 
inhibitors and signal transduction inhibitors (109,110). Two main approaches for targeted therapy are 
used; small molecule inhibitors and monoclonal antibodies (mAbs). 
 
5.1.1 Small molecule inhibitors 
Small molecule inhibitors are usually organic compounds with low molecular weight that are able to 
penetrate the cell membrane. They are specifically designed to act on specific protein targets or to 
interfere with the signaling pathways. Small molecule inhibitors could be specific for a protein target, 
or have a broad spectrum of targets. The generic names for the most of small molecules are suffixed 
with “ib” (Imatinib, Sorafenib, etc.), whereas mAbs drugs are suffixed with “mab” (Cetuximab, 
Trastuzmab, etc.) (109,110). 
 
5.1.2 Monoclonal antibodies 
Initially the generation of mAbs was done in mouse, producing mAbs that were entirely comprised of 
murine protein and were highly antigenic causing hypersensitivity in humans. To overcome these 
problems, recent mAbs are modified to have a minimum murine proportion and a maximum human 
proportion. For example, human antibodies contain 100%, humanized antibodies contain 95% and 
chimeric antibodies contain 65% human components. The suffix of the antibody indicates the 
percentage of human component, e.g., -umab (human), -zumab (humanized), -ximab (chimeric) and -
omab (murine) (109,110). The mAbs mediate their actions either through 1) Inhibiting ligand-receptor 
interaction, 2) Activating immune system, 3) Delivering an immunotoxin (111). mAbs are more 
specific than small molecule inhibitors, however the obstacles in using monoclonal antibodies include 
requirement for systemic administration, which can be painful to patient, they can only target 
extracellular antigens as they cannot penetrate the plasma membrane,  relatively expensive to 
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manufacture, and may trigger a host immune response (111). Approved small molecule inhibitors and 
mAbs targeting RTKs are summarized in Table 1. 
 
Drug type Name Targets Disease 
Antibody Trastuzmab (Herceptin) HER2 Breast cancer 
 Bevacizumab (Avastin) VEGFR Colorectal cancer 
 Cetuximab (Erbitux) EGFR Colorectal cancer 
Small molecule Imatinib BCR-ABL,    
c-KIT, PDGF 
CML, GIST 
 Gefitinib EGFR Non small-cell lung 
carcinoma 
 Sorafenib VEGFR, 
PDGFR 
Renal cell cancer 
 Laptinib EGFR, HER2 HER2-positive breast 
cancer 
 
Table 1. Approved small molecule inhibitors and monoclonal antibodies targeting members of RTKs 
in cancer (112,113). CML: Chronic myeloid leukemia, GIST: Gastrointestinal stromal cell tumor.  
 
5.2 RTKs in Cancer 
Targeted therapies for RTKs have gained much interest due to their oncogenic properties. In addition to 
regulating major signaling pathways that control cellular proliferation, apoptosis, and migration, 
mutations or overexpression of RTKs have been reported in several types of tumors (112,114-116). For 
example overexpression of HER2 and EGFR have been reported in 25% of breast cancer cases, 30–
50% of glioblastoma and 25–82% of colorectal cancer (115). These mutations generally result in a 
constitutive active receptor that can result from: 1) Mutations in the active loop of the receptor as in 
EGFR kinase domain mutation in lung cancer stabilizing the activity of the kinase domain (117), 2) 
Mutation in the extracellular domain as in HER2 mutation in pulmonary neoplasm resulting in a 
constitutive dimerization of the receptor (118), 3) Mutation in the juxta-membrane domain as in c-Kit 
and PDGFR in gastrointestinal stromal cell tumors (GIST) (119). In addition to these mutations 
overexpression of RTKs can also result from DNA translocation, as in the BCR-ABL translocation in 
chronic myeloid leukemia (CML), or from genomic amplification of EGFR in breast cancer and lung 
adenocarcinoma (116,120). 
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Although activation mutations of IGF1R have not been reported and gene amplification of IGF1R 
family is extremely rare (121), elevated IGF-1 levels have been shown in prostate and breast cancer, 
loss of genomic imprinting of IGF-2 have been reported in colorectal cancer and childhood acute 
lymphoblastic leukemia (122), and elevated levels of IGF-2 and IGF-1R in synovial sarcoma as a 
product of SS18-SSX fusion (123). In addition, extensive crosstalk between IGF-1R and other 
members of RTKs including EGFR and HER2 have been shown (122,124,125), and significant role for 
IGF-1R in HER2/EGFR resistance to targeted therapy have been reported (124-126). Furthermore, the 
recent role of nuclear translocation of IGF-1R and the association of nuclear IGF-1R with many types 
of cancers including lung, breast, and prostate cancers, and hepatocyte carcinoma (89,93) provide 
further significance for targeting IGF-1R in cancer. 
 
5.2.1 Targeting IGF-1R 
Three main approaches are used for IGF-1R targeted therapy: 1) Antibodies targeting IGF-1R, IR/IGF-
1R hybrid, 2) Neutralizing antibodies against IGF-1 and IGF-2 ligands, 3) small molecule tyrosine 
kinase inhibitors (122,127).  Antibodies targeting IGF-1R mediate their actions either through blocking 
IGF-1R from ligand binding, or mediate IGF-1R, IR/IGF-1R hybrid receptor degradation without 
affecting IR-A or IR-B. Neutralizing antibodies against IGF ligands inhibit the binding of ligands to 
both IGF-1R and IR-A without affecting IR-B, and small molecule inhibitors inhibit the kinase activity 
of the receptor (122). 
 
5.2.1.1 Monoclonal Antibodies for IGF-1R targeted therapy 
The monoclonal antibodies against IGF-1R are well tolerated as a montotherapy, with no maximum 
dose achieved at the end of Phase I, and only recorded side effect was hyperglycemia in 20% of the 
cases (122,127). Table.2 summarizes the most prominent monoclonal antibodies that target IGF-1R 
pathway. Most notable effect of mAbs in phase I and II were shown with sarcomas specially Ewing 
sarcoma and non-small cell lung cancer with reports of complete response (CR), partial response (PR) 
and prolonged stable disease (SD) with R1507 (128), IMC-A12 (129,130) and CP-751(131,132).  
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mAb Status Trail  
CP-751 
(Figitumumab) 
Discontinued after phase III 
no benefit from combination 
with carboplatin/paclitaxel 
and increased toxicity 
Phase I/II: 
Soft tissue sarcoma, Ewing Sarcoma 
Phase II: 
Prostate cancer 
 
R1507 Phase II Phase I: 
Ewing Sarcoma 
Phase II: 
Rhabdomyosarcoma, osteosarcoma, Ewing 
Sarcoma 
IMC-A12 
(Cixutumumab) 
Phase II Phase II: 
Advanced non-small cell lung cancer 
Prostate cancer 
MK0646 
(Dalotuzumab) 
Phase III Phase I: 
Solid tumors 
Phase II: 
Neuroendocrine tumor 
 
Table 2. Most prominent monoclonal antibodies that target IGF-1R pathway (122,127-132). 
 
5.2.1.2 Small molecule inhibitors for IGF-1R targeted therapy 
Due to the high homology between IR and IGF-1R tyrosine kinase domain, most small molecule 
inhibitors inhibit the activity of IR as well. However, co-inhibition of IR and IGF-1R might provide a 
better antitumor effect, as the IR signaling have been implicated in a number of tumor models (122). 
Currently the most promising small molecular inhibitors are OSI-906 (Linsitinib) in phase III, BMS-
754807 in phase II and AXL1717 (picropodophyllin) phase II. 
 
5.2.1.2.1 Picropodophyllin 
Picropodophyllin (PPP) belongs to  cyclolignans, which also include podophyllotoxin (PPT) that earlier 
has been described as an antineoplastic compound (133). This kind of chemical compounds  are also 
known as phytoestrogens (plant-derived compounds that have estrogenic
 
properties when consumed) 
(134). PPP has been  demonstrated to potently inhibit IGF-1R autophosphorylation (IC50 of 0.4 µM) in 
 29 
 
intact cells and was selective against a panel of other receptor tyrosine kinases including IR (135). The 
PPP-induced inhibition of IGF-1R phosphorylation did not  interfere with the IGF-1R tyrosine kinase at 
the ATP binding site (135), instead it is suggested  to interfere with  phosphorylation at substrate level 
(136). Furthermore, PPP was shown to induce IGF-1R downregulation through MDM2 and β-arrestin, 
without affecting IR or other RTKs (79). Inhibition of the kinase activity of the IGF-1R caused 
reduction in phosphorylation of Akt  and ERKs in IGF-I stimulated cells (135). Furthermore, PPP 
rapidly caused complete regression of autografts derived from IGF-1R positive cells and did not affect 
the tumors derived from IGF-1R negative cells (135). PPP in its oral formulation is named AXL1717. 
AXL1717  has showed promising results in a  phase I/II study involving a number of patients with 
advanced  non-small cell lung cancer of adenocarcinoma subtype, in which a progression-free survival 
of 31 weeks and an overall survival 60 weeks were reported  (137). PPP has also been shown to induce 
G2/M arrest in treated cells (138). 
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Chapter 5 
Molecular regulation of the mammalian cell cycle 
6.1 Cyclin-dependent kinases  
The process of cell proliferation is especially important for cancer cells. A hallmark of cancer is the 
abnormal regulation of cell cycle. In order for a cell to complete one round of cell division and 
reproduce an exact duplicate of itself, it has to perform five tasks in a highly ordered fashion: first to 
grow in size (G1 phase), replicate its DNA (S phase), undergo a second phase of growth (G2 phase), 
equally segregating the duplicated DNA (M phase) and finally divide into two equal daughter cells 
(139). All these crucial decisions are made by a set of information processors (cell cycle machinery) 
that integrate extracellular and intracellular signals to coordinate cell cycle events. 
The cell cycle molecular core machinery consists of a family of serine/threonine protein kinases 
known as cyclin-dependent kinases (CDKs). These are catalytic subunits, which are activated by 
associating with the regulatory subunits called cyclins. For example, CDK4/CDK6 binds to cyclin D, 
CDK2 binds to Cyclin E, A and CDK1 binds to Cyclin A, B. The activity of CDK/cyclin complexes 
is further regulated on several levels  as discussed below (140).  
I) Cyclin-dependent kinase inhibitors: CDK activity is regulated by two families of inhibitors; 
the Cip/Kip family, composed of p21
CIP1
, p27
KIP1
 and p57
KIP2
 and the INK4 proteins, 
composed of p16
INK4A
, p15
INK4B
, p18
INK4C
 and p19
INK4D
. INK4 proteins inhibit cyclin-CDK 
interaction, while Cip/ Kip proteins binds to CDK–cyclin complexes and disrupt ATP 
binding and substrate access (141). 
II) Phosphorylation of the CDK subunit can have both positive and negatives effects on its 
activity. For example, phosphorylation of threonine  161 (T161) in Cdc2 is required in order 
for the full activity of the CDK/cyclin complex (142). However, phosphorylation of 
threonine 14 (T14) and tyrosine 15 (Y15) of Cdc2, inhibits CDK activity even when it is 
phosphorylated at T161.  
III) Proteasome protein degradation:  Two types of E3 ubiquitin ligases have important roles in 
regulating cell cycle the Skp1–Cul1–F-box protein (SCF) complex family and the anaphase 
promoting complex/cyclosome (APC/C). The SCF and APC/C complexes belong to a 
broader family of cullin–RING ubiquitin ligases (CRLs), and have important functions in 
regulating cell cycle through targeting cell cycle proteins for ubiquitination and subsequent 
proteasome degradation. The SCF complex is composed of four components; Skp1, cullin 
protein Cdc3/Cul1, an F-box containing protein, and the RING protein Rbx/Roc1/Hrt1. The 
F-box protein determines the specificity of the complex, and access to F-box proteins is 
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usually regulated to control ubiquitination of the target protein. For example, in many 
substrates pre-phosphorylation is required for the interaction of SCF complex with its 
cognate F-box protein, and/or the F-box protein are usually targeted for degradation through 
autoubiquitination. The APC/C is active throughout mitosis and G1 phase, it is a large, 
multicomponent protein complex composed of more than a dozen individual proteins. The 
activity of the APC/C is regulated by CDK phosphorylation of core APC/C components and 
pseudo-substrate inhibitors. 
 
6.2 Regulation of cell cycle during G1 phase:  
In early G1 phase, extracellular mitogenic signals stimulate the release of INK4 inhibitors from the 
CDK4/6, allowing the association of CDK4/6 with cyclin D. CDK4/6 being active induces the 
phosphorylation of a group of proteins called pocket proteins, including the retinoblastoma protein 
(Rb), the retinoblastoma-like protein 1 (p107) and the retinoblastoma-like protein 2 (p130). In the 
non-dividing state the Rb protein binds to the activator E2F family (E2F 1,2,3), a family of 
transcription factors that regulate expression of G1/S phase proteins through binding to E2F-
responsive promoters, and inhibit them from binding to the cognate E2F-responsive promoters. At 
the same time p107 and p130 bind to repressor E2F family of proteins (E2F 4,5), allowing them to 
bind to E2F-responsive promoters and inhibit cell cycle protein expression. Phosphorylation by CDK 
4/6 allow the release of E2F proteins from Rb and pocket proteins, allowing the binding of activator 
E2F proteins and inducing expression of G1/S cell cycle proteins including cyclin D1, cyclin A, 
cyclin E (143,144), p21
CIP
, CDK2, Cdc2, and Cdc25c (145). Activator E2F proteins induce the 
expression of SCFFbx4/alphaB-crystallin
 
protein complex which targets ubiquitination and degradation of cyclin 
D (146), as well as the expression of repressor E2F proteins (6,7) acting as a negative feedback loop. 
In addition to inducing the expression of SCF
SKP2
 complex required for p21 and p27 degradation to 
allow the accumulation of cyclin E which marks the ends of early G1 phase and the start of transition 
towards G1/S phase (reviewed in(147)).  
 
6.3 Regulation of cell cycle during G1/S phase:   
During G1/S-phase a group of protein called pre-replication complex (pre-RC) has to be bound to the 
origin of replication to initiate replication during S-phase. The pre-RC is composed of origin 
recognition protein complex (ORC), minichromosome maintenance protein complex (MCM 2-7), 
CDC6 and CDC10-dependent transcript 1(CDT1). The ORC is bound to the origin of replication 
throughout most of the cell cycle to form the post-replication complex (post-RC). By the end of 
mitosis, and through anaphase the degradation of CDK1 and another protein called Geminin by the 
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APC/C, allow the binding of CDT1 and CDC6 to the ORC. Geminin inhibits CDT1 activity and 
prevent from binding to the ORC, and the high CDK activity phosphorylates CDT1 and marks it for 
degradation by SCF
SKP2
. Binding of CDC6 and CDT1 to the ORC create a footprint for MCM 
loading for the formation of pre-RC. For replication firing during S-phase, the MCM 2-7 helicase 
needs to be activated and the pre-initiation complex (pre-IC) is required to be formed. The high 
CDK2, and the DBF4-dependent kinase activity (DDK; also known as the CDC7–DBF4 
complex) during S-phase is required for phosphorylation and activation of the MCM 2-7 complex, in 
addition to phosphorylation of several other factors including (CDC45, GINS, treslin, DNA 
topoisomerase 2-binding protein 1 (TOPBP1) and DNA polymerase ε (Pol ε)) which are required for 
formation of pre-IC. CDC45 and GINS are required for the activation of the MCM helicase, and the 
formation of CMG complex at the replication fork (CDC45, MCM, GINS). The phosphorylation of 
TOPBP1 and treslin is required for loading of CDC45 and GINS to the pre-IC. Replication firing 
then recruits additional factors including proliferating cell nuclear-antigen (PCNA), replication factor 
C (RFC), replication protein A (RPA) and DNA polymerases. To prevent origin re-replication,  
binding of Cdt1 to the PIP domain of the PCNA marks the Cdt1 for proteasome degradation, and the 
high level of CDK during S-phase induce activation of Geminin and inhibition of CDT1, in addition 
to nuclear export of CDC6 (reviewed in (148,149)). 
 
6.4 Regulation of cell cycle during mitosis 
The M phase is regulated by CDK1 kinase and the associated cyclin B or M-phase promoting factor. 
Cyclin B expression start to increase by late S phase through activation of NF-Y, B-Myb, FoxM1 
transcription factors induced by CDK2/Cyclin A expression, peak by the beginning of mitosis and 
start to decline by the end of mitosis through proteosomal degradation by APC/C. CDK1/Cyclin B 
activation is mainly regulated by phosphorylation, through inhibitory phosphorylation by Wee1/Myt1 
kinases on T14/Y15 and by activating phosphorylation on T161 by CDK-activating kinase (CAK). 
CAK is fairly active throughout mitosis, suggesting that regulation is mainly mediated by 
Wee1/Myt1 kinase. At the beginning of mitosis Wee1/Myt1 inhibition of CDK1/Cyclin B is 
dominant, the activation of CDC25 phosphatase allow the removal of the inhibitory phosphorylation 
from CDK1, which in turn phosphorylate CDC25 for further activation and phosphorylate Wee1 for 
proteasomal degradation. The Wee1/CDC phosphatase are regulated by another protein called Polo-
like kinase 1 (PLK1). The PLK1 composed of two domains (Polo-box domain) and kinase domain, 
separated by linker domain. Phosphorylation of kinase domain by Aurora A kinase activates PLK1 
kinase, which then bind to phospho-site on the target protein through its Polo-box domain, inducing 
conformational changes in the PLK1 kinase allowing the additional phosphorylation of the target 
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protein by the kinase domain. The PLK1 add additional phosphorylation, after the initial 
phosphorylation by CDK1/cyclin B, to CDC25 for full activation and to Wee1 kinase for 
ubiquitination by F-box E3 ligases and proteasomal degradation. In addition, PLK1 have other cell 
cycle functions including centrosome maturation, chromosome attachment and cytokinesis.  
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7. Chapter 6 
Maintaining genome stability 
 
7.1 Genomic instability 
Genomic instability is the inability of cancer cells to maintain proper number and structure of 
chromosomes. Genome instability arises if cells initiate mitosis with partially replicated chromosomes, 
miss-segregated chromosomes or unrepaired DNA-damage such as double strand breaks (DSB). Some 
DNA aberrations arise via physiological processes, such as DNA mismatches occasionally occurring 
during DNA replication, and DNA strand breaks caused by non-enzymatic methylations, or by 
reactive-oxygen compounds. DNA damage can be also caused by environmental factors such as 
ultraviolet light (UV), ionizing radiation (IR), or through DNA-damaging chemicals such as aflatoxins 
or tobacco products (150,151). 
To avoid transmission of genome alterations to daughter cells, cells have evolved checkpoint pathways 
during cell cycle divisions to arrest cell cycle progression and promote DNA repair or, in case of 
unrepairable damage, stimulate cell death and/or senescence. In response to DNA damage, cell cycle 
checkpoints can be activated in G1 phase, in S phase and at the G2/M transition in addition to the 
spindle assembly check point for chromosome segregation during mitosis. The overall cellular response 
to DNA damage is known as DNA damage response (DDR), and involves sensor proteins that detect 
DNA damage and transmit the signal through mediator proteins to downstream effectors that, in turn, 
arrest cell cycle progression and promote repair on induce apoptosis (reviewed in (152-155) . 
 
7.1.1 ATR DNA damage response signaling pathway 
The cellular responses to DNA damage during cell cycle checkpoints are controlled by the sensor 
proteins ATM (ataxia telangiectasia mutated) and ATR (ATM and Rad3-related). These proteins 
belong to a family of Ser/Thr protein kinases called phosphoinositide-3 –kinase related kinase (PIKKs), 
which also include DNA-PK (DNA-dependent protein kinase) that plays an important role during DNA 
repair (156). The ATR generally recognizes single strand breaks (SSB) and replication stalling during 
S-phase and G2/M phase of cell cycle. Replication stalling, or single strand breaks result in free single 
stranded DNA (ssDNA), which is soon coated by RPA. The RPA-ssDNA recruits ATR, where ATR 
associates with RPA through its targeting subunit ATR interacting protein (ATRIP). DNA damage is 
recognized independently by a heterotrimeric ring-shaped protein complex related in structure and 
sequence to PCNA known as the 9-1-1 (Rad9–Hus1–Rad1) checkpoint clamp.  As with PCNA, the 9-
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1-1 complex is loaded through a damage-specific clamp loader Rad17 and RFC. The 9-1-1 complex 
associates with TopBP1, which is required for ATR activation  (152,157). Activated ATR then 
phosphorylates an adaptor protein called Claspin, phosphorylated Claspin act to recruit and bring 
CHK1 kinase to ATR for phosphorylation and activation on S
345/317
. CHK1 acts as the mediator protein 
in the DNA damage response of ATR signaling, transmitting the signal from ATR to effector proteins. 
Phosphorylated Claspin also binds to phosphorylated Rad17, which is required for sustained CHK1 
phosphorylation. CHK1 being activated leaves the chromatin to the nucleoplasm where it 
phosphorylates CDC25A and target it for proteasome degradation, or CDC25C and target it for 
association with 14-3-3 and cytoplasm export. In addition, CHK1 phosphorylates and activates Wee1 
kinase. This functions in preventing cell cycle progression by inhibiting CDK2 and CDK1, allowing 
the cell to repair DNA damage (158). 
In addition to inhibiting cell cycle progression, CHK1 participate in homologous recombination by 
recruiting Rad51 (159), in regulating PCNA monoubiquitination and Translesion synthesis (TLS) 
pathway (160), discussed further below, and in stabilizing replication fork and/or the restart of 
replication fork (158). 
 
7.1.2 ATM DNA damage response signaling pathway 
ATM exists as inactive homo-dimer, and generally recognizes DSBs through association with 
Mre11/Rad50/Nbs1 (MRN complex). The association of ATM to MRN complex induces 
autophosphorylation of ATM and dissociation into active monomers (156). The activated ATM then 
phosphorylate the mediator protein CHK2 and histone 2X variant known as γH2AX, which act as 
recruitment platform for mediator of DNA damage checkpoint protein 1 (MDC1). MDC1 acts to 
amplify the signal by recruiting additional MRN complex which further recruits additional ATM 
(156).Activated CHK2 then, phosphorylates several nuclear proteins including p53, DNA repair 
proteins (BRCA1, BRCA2) and cell cycle proteins (CDC25A, CDC25C, RB). This leads to cell cycle 
arrest by the degradation of CDC25A and CDC25C, or through upregulation of p21 through activation 
of p53 which then binds to and inhibits CDK/Cyclin complexes (161). 
MDC1 is also phosphorylated by ATM which results in recruitment of E3 ligases RNF8 and RNF168 
that leads to ubiquitination of histone 2. Histone 2 ubiquitination and histone 4 lysine 20 (H4K20) 
methylation recruit 53BP1 to the damage site which is further phosphorylated by ATM and act to 
activate the non-homologous end joining repair pathway (NHEJ) (155). During S phase the elevated 
CDK activity result in phosphorylation of NBS1 subunit of MRN complex, in addition to the DNA-end 
processing factor CtIP and BRCA1. Phosphorylated NBS1 binds to CtIP which then recruits and binds 
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to BRCA1. BRCA1 counteracts and inhibits the action of 53BP1 and activates repair through 
homologous recombination (155). 
Although ATR and ATM are generally known to respond to single and double-strand DNA damage 
respectively, their signaling pathways are interconnected. For example, double-strand breaks activate 
ATM, which along with CtIP 5-3’ resection activity, generates ssDNA leading to consequent ATR 
activation (162). On the other hand, ATR activated in response to UV-induced DNA damage activate 
ATM by phosphorylating ATM at its autophosphorylation site S1981 (163). 
 
7.1.3 PCNA and DNA damage tolerance pathway 
The conformation of DNA polymerases does not allow for stable interaction with the template DNA. 
To strengthen the interaction between DNA template and polymerases, DNA sliding clamp is required 
(149). In eukaryotes, this sliding clamp is the PCNA, which forms a homotrimer ring-like structure, 
each monomer contains 2 domains I, comprised of residues 1 to 117, domain II, comprised of residues 
135 to 258, connected by the interdomain-connecting loop (IDCL) , comprised of residues 118 to 134 
(Fig. 3) (164). 
 
 
Figure 3. Structure of PCNA. (A) Front view showing Domain I, II and IDCL. (B) Side view 
showing ubiquitin site (165). 
 
The PCNA homotrimer ring has a front face with C-terminus, where most interactions with DNA 
polymerases and other proteins occur (166-168) and back face with N-terminus, where K-164 site for 
ubiquitination and SUMOylation is found (169). Most proteins bind to PCNA through a conserved 
sequence called PIP (PCNA interacting peptide) box, at the hydrophobic pocket beneath the IDCL on 
the front face. PIP motifs are sequences of eight amino acids, Q-x-x-J-x-x-w-w, in which Q is a 
conserved glutamine, J is a moderately aliphatic residue (leucine, isoleucine, or methionine) and w is an 
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aromatic residue (phenylalanine or tyrosine) (170,171). In addition a second interacting motif termed 
AlkB homolog 2 PCNA-interacting motif (APIM) is also common among DNA repair proteins 
(170,171). 
 
7.1.3.1 PCNA and DNA replication 
After the formation of the pre-initiation complex during S-phase, see chapter 5, the CMG complex 
starts unwinding the DNA and the ssDNA soon will be coated with RPA. DNA polymerase α/primase 
start forming a short DNA/RNA hybrid primer, which is recognized by the RFC that loads the PCNA 
in the proper orientation. The PCNA acts as the processivity factor (the average number of  nucleotides 
added before dissociation from DNA) for pol ε in the leading strand and for pol δ in the lagging strand 
(148,149,164,171). In yeast PCNA is SUMOylated on K-164 by the E2/E3 ligases Ubc9/Siz1 
(169,172), this prevents recombination during S-phase (173,174).  
 
7.1.3.2 DNA damage tolerance pathway 
In addition to DNA replication, PCNA has additional roles in DNA repair and the recently identified 
DNA damage tolerance pathway. During S-phase, replication-blocking lesions must be repaired or 
bypassed in order to complete DNA replication. Prolonged stalling of replication forks can lead to 
fork collapse, DSBs, chromosomal rearrangements and genomic instability (175-177). DNA damage 
tolerance mechanisms, or post-replication repair processes, allow the cell to replicate over 
polymerase-blocking lesions. There are three types of DNA-damage tolerance: 1) An error-prone 
translesion DNA synthesis (TLS), 2) An error-free TLS and 3) An error-free DNA damage silencing 
(DDS), or template switching. All three pathways require PCNA and depend on the ubiquitination 
status of PCNA (178,179). 
TLS is a conserved process that allows the replication machinery to bypass DNA lesions through the 
exchange of the high-fidelity DNA polymerases to low-fidelity DNA polymerases (178,179). Unlike 
the high-fidelity DNA polymerases such as Polα, Polδ and Polε, low-fidelity or Y-family of TLS 
polymerases including Polη (eta), Polκ (kappa), Polι (iota) and Rev1 contain larger active sites 
capable of accommodating distorted bases and mismatched base pair (180,181). Thus, the general 
conception that TLS polymerases are often considered error-prone. However several TLS 
polymerases have been shown to display proper base pairing opposite to specific lesions (180,181), 
for example, the Polη preferentially inserts two “A”’s opposite a thymine dimer, a common UV 
photoproduct (182,183) and Polκ has been shown to accurately bypass benzopyrene-induced guanine 
adducts (184,185). Thus, TLS can be either mutagenic or accurate, depending on the type of lesion 
and which TLS polymerase is used (178).  
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Much less is known about DNA damage silencing or template switching, an error-free form of DNA 
damage tolerance. As the name implies, template switching is thought to utilize the undamaged sister 
chromatid as the template to carry out limited DNA replication. Two models for template switching 
have been proposed, one involving fork regression using the nascent sister chromatid, leading to the 
formation of what is called chicken foot structure, and the other involving invasion of the sister 
chromatid in a manner similar to homologous recombination (178,179,186,187). 
Interestingly, all DNA damage tolerance pathways require PCNA, and different covalent 
modifications of PCNA by ubiquitin (Ub) determine which tolerance pathway will be utilized. Mono- 
and polyubiquitination of PCNA are mediated by two distinct sets of E2–E3 enzymes that operate in 
a linear fashion (188). PCNA is monoubiquitinated by the E2/E3 RING ligases Rad6/Rad18 on K-
164 on the back face of the homotrimer PCNA ring (169,189,190). PCNA monoubiquitination is 
required for the subsequent polyubiquitination mediated by the E2 Mms2-Ubc13 and the E3 
SNF2 histone linker PHD RING helicase (SHPRH), helicase-like transcription factor (HLTF) 
(equivalent to S. cerevisiae. Rad5) ligases (175,178,191-193).  Polyubiquitination of PCNA is 
mediated by the attachment of ubiquitin through the K63-linkages, which is different from the 
conventional K48-linked ubiquitin chains that target proteins for degradation by the 26S proteasome 
(194,195). Recent data have showed that polyubiquitination of PCNA functions to prevent the 
binding of pol δ to PCNA, and thus prevents normal replication (196). 
 
7.1.4 Spindle assembly checkpoint 
The spindle assembly checkpoint (SAC) is a mitotic checkpoint that monitors the attachment of 
chromosomes to the kinetochore spindles and prevents the progression of anaphase until all 
chromosomes are correctly attached to the bipolar spindle. Upon spindle attachment, Cdc20 and APC 
ubiquitin ligase are activated, leading to ubiquitination and proteolytic degradation of cyclin B, and 
securin, which inhibits separase. Following degradation of securin, the activated separase targets 
cohesin, a protein complex that holds sister chromatids together, causing sister chromatid separation, 
and, anaphase onset.  
 
7.1.5 Anti-mitotic drugs and mitotic catastrophe 
Mitotic catastrophe, as defined in 2012 by the International Nomenclature Committee on Cell Death, is 
a bona fide intrinsic oncosuppressive mechanism that senses mitotic failure and responds by driving the 
cell to an irreversible anti-proliferative fate of death or senescence, thus preventing aneuploidy and 
genome instability. This form of cell death does not require caspase 9 or 3 and can still occur in the 
presence of caspase inhibitors. Instead it requires CDK1 and BCL-2 family activity (197-201). BCL-2 
 39 
 
is a large family of proteins that include prosurvival proteins (Bcl-2, Bcl-XL , BCL-W, Mcl1, A1, and 
Bcl-B), proapoptotic effector proteins (Bax, Bak, and Bok) as well as BH3-only proteins (Bim, PUMA, 
Bad, NOXA, Bik, Hrk, Bmf, and tBid) (202). Active CDK1 phosphorylates Bcl-2, Bcl-XL blocking 
heterodimer formation with proapoptotic members, Bax and Bak, resulting in oligomerization of the 
proapoptotic factors at the outer mitochondrial membrane, release of cytochrome C, and thereby 
apoptosis (203). In addition, CDK1 also phosphorylates Mcl-1 and targets it for ubiquitination and 
proteasome degradation, leading to proapoptotic factors oligomerization at the outer mitochondrial 
membrane and apoptosis (198,199). 
It is then proposed that during a typical mitotic division, the levels of CDK1 activity are not sufficient 
enough to promote cell death through phosphorylation and degradation of Mcl-1, due to the 
degradation of cyclin B by the APC. However, during a mitotic catastrophe, the prolonged mitotic 
arrest results in prolonged CDK1 activation which is sufficient enough to promote cell death (199). 
Thus the proposed model that the fate of cells during mitotic catastrophe will be determined through a 
balance of CDK1 activity and apoptotic signals, leading to three possible anti-proliferative fates: 1) If 
levels of cyclin B1 are high, resulting in high CDK1 activity, the cell will undergo death in mitosis 
(204), 2) If the levels of cyclin B start to decline mitotic slippage will occur and the cell will undergo 
death in G1 phase (205), 3) Cells can undergo senescence after mitotic slippage (199). Although it was 
shown that caspase activity was not required for mitotic catastrophe or cell death after mitotic slippage 
(201), cell death can also occur in a caspase-independent manner (206). However, the molecular signals 
that link these events during mitotic catastrophe remain poorly understood. 
 
Mitotic catastrophe is usually accompanied by prolonged mitotic arrest, and drugs mostly induce 
mitotic catastrophe through interfering with microtubules. However, due to the side effect of 
microtubule-targeting agents, including neutropenia, neuropathy, and reversible myelosuppression 
(207,208), recent research efforts have focused on the development of non-microtubule antimitotic 
agents, such as those targeting mitotic motor proteins and mitotic kinases (199,200). These can cause 
mitotic catastrophe through : 1) Abrogating G2 checkpoint or inducing persistent DNA damage during 
chromosomal segregation, 2) Interfering with spindle formation or mitotic machinery that activate the 
SAC, 3) Inhibiting cytokinesis that will lead to mitotic catastrophe in the next round of mitosis (199). 
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7.1.5.1 Microtubule- targeting agents 
Microtubules are dynamic structures composed of α and β–tubulin molecules that are constantly 
integrated by polymerization, named the plus end, or shed off by depolymerization, named the minus 
end, at both ends of microtubule (209). Drugs that act on microtubules can be divided into two groups: 
microtubule polymerizing agents that bind to taxoid binding site on beta tubulin, including taxanes 
(paclitaxel and docetaxel), and the microtubule depolymerizing agents, which bind to one of two 
domains on tubulin, the “vinca” domain and the “colchicine” domain. The Vinca-domain agents 
include the vinca alkaloids (vinblastine and vincristine) and the colchicine-domain agents include 
colchicine and its analogs, podophyllotoxin (207). Both classes of drugs alter microtubule dynamics, 
thus preventing the formation of normal bipolar spindle and chromosome biorientation, leading to 
mitotic catastrophe (199,200). 
 
7.1.5.2 Mitotic kinesins 
Mitotic kinesins are a group of motor proteins that function exclusively in mitosis and are involved in 
bi-polar spindle assembly. This includes Eg5, KIFC1 and KIF2A. Eg5 is a plus end motor protein, 
moves towards the plus end of the microtubule. Active Eg5 is a homotetramer that cross-link and 
translocate along two adjacent microtubules with each dimer interacting with a single microtubule fiber 
(210,211). Eg5 creates necessary forces for spindle formation, thus Eg5 inhibition results in the 
formation of monoaster spindles leading to mitotic arrest and apoptosis or mitotic catastrophe 
(199,200). 
 
7.1.5.3 Aurora and polo-like kinases 
The aurora kinase is a family of serine/threonine protein kinases including Aurora A, Aurora B and 
Aurora C kinases. Aurora A is localized to centrosomes during interphase and to spindles poles and 
spindle microtubules during mitosis, where it participates in several processes required for bipolar 
spindle formation including PLK1 activation, centrosome separation and microtubule dynamics. 
Aurora B localizes to kinetochores from prophase to metaphase and to the spindle midzone in 
cytokinesis where it forms a part of the Chromosome Passenger Complex (CPX) that plays critical 
roles during chromosome segregation and microtubule-to-kinetochore attachments (212,213).  Little is 
known about Aurora C, but it is mainly expressed in the testis. Inhibition of the Aurora B kinase causes 
mitotic slippage without cytokinesis, causing aneuploidy, and continued inhibition results in very large 
multiploid cells that eventually undergo apoptosis or senescence (200,214-216). Inhibition of Aurora A 
kinase causes defects in mitotic spindle assembly, mitotic arrest and apoptosis (212).  
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Polo-like kinases are yet another family of Serine/Threonine (Ser/Thr) kinases with key roles in 
mitosis. Mechanistically, PLK1 is activated by Aurora-A, as explained in chapter 5, and functions to 
promote CDK1 activation, checkpoint recovery and centrosome separation. The inhibition of PLK1 
kinase does not block mitotic entry; instead induces a metaphase arrest due to monopolar spindle 
formation (217).  
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Results and Discussion 
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8. Chapter 7 
Results and Discussion 
8.1 Paper I 
PICROPODOPHYLLIN CAUSES MITOTIC ARREST AND CATASTROPHE BY 
DEPOLYMERIZING MICROTUBULES VIA INSULIN-LIKE GROWTH FACTOR-1 
RECEPTOR-INDEPENDENT MECHANISM. 
 
PPP has been demonstrated to inhibit IGF-1R and/or its signaling in numerous cell systems (218,219), 
and in tumor xenografts (220,221), as well as in granulocytes in treated patients (137). A unique feature 
for PPP is that it also induces G2/M arrest in treated cells (138). We sought to investigate the 
mechanism behind PPP-induced G2/M arrest in detail. Using fluorescence microscopy, flow cytometry 
and time-lapsed video microscopy, we demonstrated the mitotic block of PPP in various cell lines and 
xenograft, even in igf1r
-/-
 cells (R-) cells, but not in normal hepatocytes or normal cells from A549 
xenografts, indicating that the mitotic arrest was IGF-1R independent. Trying to reveal the mechanism 
through which PPP induces the mitotic arrest, we found a high activation of CDK1, increased CDK1 
phosphorylation of T161, along with increased expression and association with cyclin B. A prolonged 
mitotic arrest with increased cyclin B expression represents a new mechanism of cell death called 
mitotic catastrophe, a caspase independent cell death pathway (199). With this hypothesis in mind, we 
investigated the apoptotic effect of PPP and found it to be independent of caspases, but occurred 
through inhibition of MCL-1, as has been reported for mitotic catastrophe (198). We also found PPP to 
interfere with centrosome and mitotic spindle formation during mitosis. This effect was shown to be 
independent from PLK1 kinase or Eg5 kinesin but through interference with microtubule dynamics. 
However, PPP was shown to not bind to microtubules. This is compatible with results from clinical 
studies, in which PPP has not shown any neurotoxicity. Neurotoxicity is a quite common and serious 
adverse effect of microtubule inhibitors used in cancer therapy. 
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8.2 Paper II 
SUMO-MODIFIED INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (IGF-1R) 
INCREASES CELL CYCLE PROGRESSION AND CELL PROLIFERATION. 
 
IGF-1R has been shown to be SUMOylated on three lysine residues (Lys1025, Lys1100 and Lys1120), 
and this SUMOylation was shown to be important for the nuclear translocation of the receptor (90,92), 
where it can bind to several enhancer regions and regulate gene expression (96,108). Nuclear IGF-1R 
has been associated with many types of cancers including lung, breast, and prostate cancers, and 
hepatocyte carcinoma (89,93), suggesting a possible role for nuclear IGF-1R in regulating 
tumorigenicity. To verify such hypothesis, we investigated the effect of IGF-1R SUMOylation and 
nuclear translocation on cellular proliferation. 
We transfected igf1r
-/-
 knockout cell line with either wild type (WT), triple SUMOylated mutant IGF1R 
(TSM) or empty plasmid (R-), and used these cell lines as a model in our study. We showed that both 
the WT and TSM cell line could maintain same level of AKT and ERK phosphorylation, indicating that 
the canonical pathway of IGF-1R was not affected. However, we found an unexpected but low level of 
TSM translocation to the nucleus, which could be mediated by dimerization to insulin receptor (IR), as 
shown by co-immunoprecipitation (co-IP). We found that WT transfected cell line had higher 
proliferation rate than the TSM or the R- cells, and that this effect was not mediated through difference 
in cell death. To investigate the mechanisms behind the higher proliferation rate in WT cells, cell cycle 
progression was followed after cellular synchronization using flowcytometry. We found that WT cells 
have a much higher G1/S progression. This was shown to be due to increased G1 phase cyclin D 
expression, followed by increased expression of G1/S CDK2 and cyclins A and B, along with increased 
inhibition of p27, suggesting a potential role for SUMO/nuclear IGF-1R in regulating cell cycle.  
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8.3 Paper III 
INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR PHOSPHORYLATES 
PROLIFERATING NUCLEAR ANTIGEN AND RESCUES STALLED REPLICATION 
FORKS AFTER DNA DAMAGE. 
 
In this study, we tried to identify novel binding partners of nuclear IGF-1R. Initially we made co-IP of 
IGF-1R from the hESC line WA01, and the associated proteins were identified by mass spectrometry. 
PCNA was identified as one of main proteins binding to IGF-1R, which was validated in several cell 
types by co-IP after cell fractionation. Using igf1r
-/-
 knockout mouse cells (R-) and an R- stable 
transfectant with IGF1R (R+), we found that PCNA from R+ was tyrosine phosphorylated and 
ubiquitinated but not PCNA from R- cells. IGF-1R mediated PCNA ubiquitination was correlated to 
recruitment of E2/E3 ligases mediating DDT (Rad18, UBC13/SHPRH, HLTF) (178,188,222,223). We 
investigated the effect of DNA damage, using ultraviolet radiation (UV) and methyl methanesulfonate 
(MMS) on PCNA ubiquitination.  While it was found to be absent in R- , PCNA ubiquitination was 
strongly increased in R+ cells upon DNA damage.  However, this response disappeared/decreased in 
R+ cells after treatment with an IGF-1R inhibitor. A potential role of IGF-1R in the DDT pathway was 
further supported by results from replication fork restart analysis using DNA fiber assay and S-phase 
progression using cell cycle analysis of DNA damage-exposed R+ and R- cells.  
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9. Chapter 8 
Concluding Remarks 
 
Since the 90s IGF-1R has been increasingly reported to be important for cancer cell growth and 
survival, as well as the receptor exhibits substantial expression in malignant tissues. This has raised 
expectations of its use as a target for cancer therapy. Accordingly, several pharmaceutical companies 
started producing specific antibodies against the receptor. Several phase 3 clinical trials were 
performed, but all of them reported disappointed results (224). One explanation could be that the 
antibodies can only target IGF-1R localized on the cell membrane. Cell membrane IGF-1R activates 
the so-called canonical pathways, which other receptor tyrosine kinases also do. However, recent 
discovery of and studies on nuclear IGF-1R have provided new insights into actions of IGF-1R.   
 
The mechanisms by which PPP causes G2/M arrest were here characterized in detail. PPP induced 
mitotic arrest causing mitotic catastrophe. These events were confirmed to be independent to IGF-1R.  
The mitotic arrest and catastrophe induced by PPP may potentiate its anti-cancer efficacy, without 
leading to irreversible adverse effects. 
 
SUMOylation of IGF-1R has earlier been shown to be required for nuclear IGF-1R’s transactivating 
effect. Here it is shown that SUMOylation of IGF-1R increases cell proliferation through directing 
expression of cyclins and related cell cycle proteins. Evidence that nuclear IGF-1R regulates DNA 
damage tolerance pathway through posttranslational modifications of PCNA is also provided.  
 
These identified novel properties of nuclear IGF-1R support involvement of new mechanisms 
regulating cell proliferation and genetic stabilization, independent to the canonical IGF-1R pathways. 
Such mechanisms may contribute to increased understanding of IGF-1R actions in cancer and possibly 
in development of improved therapy. The mitotic block and catastrophe induced by PPP may explain a 
part of its antitumor efficacy. 
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